==== Front BMC Cancer BMC Cancer BMC Cancer 1471-2407 BioMed Central London 7651 10.1186/s12885-020-07651-1 Research Article The association of leptin and adiponectin with hepatocellular carcinoma risk and prognosis: a combination of traditional, survival, and dose-response meta-analysis Zhang Lilong 1 Yuan Qihang 2 Li Man 1 Chai Dongqi 1 Deng Wenhong wenhongdeng@whu.edu.cn 1 http://orcid.org/0000-0002-3854-0083Wang Weixing sate.llite@163.com 1 1 grid.412632.00000 0004 1758 2270Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan, 430060 Hubei China 2 grid.452435.10000 0004 1798 9070Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011 Liaoning China 30 11 2020 30 11 2020 2020 20 11673 8 2020 17 11 2020 © The Author(s) 2020Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Background An increasing number of studies have focused on the association between leptin, adiponectin levels and the risk as well as the prognosis of hepatocellular carcinoma. However, the reported results are conflicting. Methods A meta-analysis was performed to assess the correlation between leptin, adiponectin levels and risk and prognosis of hepatocellular carcinoma (CRD42020195882). Through June 14, 2020, PubMed, Cochrane Library and EMBASE databases were searched, including references of qualifying articles. Titles, abstracts, and main texts were reviewed by at least 2 independent readers. Stata 16.0 was used to calculate statistical data. Results Thirty studies were included in this meta-analysis and results showed that hepatocellular carcinoma group had significantly higher leptin levels than the cancer-free control group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000), the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002). Hepatocellular carcinoma group had significantly higher adiponectin levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but no statistical difference compared with the cancer-free control group (SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213). The leptin rs7799039 polymorphism was associated with increased risk of hepatocellular carcinoma (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). There were linear relationships between adiponectin levels and the risk of hepatocellular carcinoma (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001). In addition, the results showed that high/positive expression of adiponectin was significantly related to lower overall survival in hepatocellular carcinoma patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002); however, there was no significantly association between the leptin levels and overall survival (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766). Conclusion The study shows that high leptin levels were associated with a higher risk of hepatocellular carcinoma. Adiponectin levels were proportional to hepatocellular carcinoma risk, and were related to the poor prognosis. Keywords LeptinAdiponectinHepatocellular carcinomaMeta-analysisissue-copyright-statement© The Author(s) 2020 ==== Body Introduction Hepatocellular carcinoma (HCC) accounts for the sixth most common cancer in the world and the fourth leading cause of cancer death globally [1], and has highly invasive and aggressive behavior [2]. Generally, HCC is secondary to liver cirrhosis or viral hepatitis. About 80% of patients newly infected with the virus will develop chronic infections, and 10–20% of them will develop liver cirrhosis within 20–30 years, and 1–5% of them will meet advanced liver cancer [3]. Studies have further identified obesity, particularly abdominal obesity, as a potential risk factor for HCC. Therefore, leptin and adiponectin, as the most plenteous and the best-studied obesity-related adipokines, may play an important role in the development of HCC [4, 5]. Leptin is well known as a regulator, which acts in energy expenditure and food intake. Research on leptin has shown that it not only plays a key role in metabolism, but also mediates tumor development by enhancing tumor angiogenesis, promoting cell proliferation, migration, invasion, and inhibiting tumor cell apoptosis [6]. Leptin acts on receptors expressed in many tissues, including the liver. Adiponectin, also known as AdipoQ, was first described by Arita et al. It has liver-protecting and anti-inflammatory properties [7, 8]. The beneficial effects of AdipoQ have been observed in alcoholic and non-alcoholic liver disease models [9]. Animal studies also proven that AdipoQ has a protective effect in liver cancer and cirrhosis [10, 11], and high AdipoQ levels in patients with cirrhosis and HCC are related to disease progression [12, 13]. In recent years, reports on the correlation between leptin, AdipoQ levels and HCC have gradually increased, and some studies have tried to clarify the role of the two in HCC. Unfortunately, the reported results are conflicting. Therefore, we conducted a meta-analysis to systematically determine the relationship between leptin, AdipoQ levels and HCC risk and prognosis. Methods The protocol for this meta-analysis is available in PROSPERO (CRD42020195882). Literature search strategy The PubMed, EMBASE, and Cochrane Library Databases were explored on June 14, 2020, limited to the English language. The following terms were searched in [Title/Abstract]: Adiponectin [MeSH], AdipoQ, Adipocyte Complement Related Protein 30 kDa, Adipose Most Abundant Gene Transcript 1, apM 1 Protein, ACRP30 Protein, Adipocyte, C1q and Collagen Domain Containing Protein, Leptin [MeSH], Obese Protein, Obese Gene Product, Ob Gene Product, Ob Protein, Liver Neoplasms [MeSH], Liver Neoplasm*, Hepatocellular Cancer*, Hepatic Cancer*, Liver Cancer*, Cancer of Liver. Besides, the reference lists of included articles were manually searched. Study selection criteria Inclusion criteria: (1) studies were focused on the correlation between leptin or AdipoQ levels and HCC risk, and provided full text and complete data in HCC patients and cancer-free controls (CFC), or (2) investigated the correlation between AdipoQ or leptin levels and the prognosis of HCC, and provided sufficient information to get the hazard ratio (HR) and 95% confidence intervals (CIs). Exclusion criteria: conference abstracts, case reports, comments, review, and experimental animal studies were excluded. When studies reported on the same or overlapping patient populations, only the study with the most complete data set and the most rigorous methodology was used. Data extraction Basic information from each study were extracted: the first author, year of publication, country, study design, study period, number of subjects, and sample source. Also, the following information was extracted in Table 1: the source of the case group, the source of the CFC group, age, gender, body mass index, measurement indicators, and detection methods. Table 2 summarized the following information: source of cases/controls, matching variables, single nucleotide polymorphisms, genotyping methods, frequency of cases, and control genotypes. In Table 3, the following information was selected: follow-up, measured indicators, detected methods, cut-off values, survival analysis, HR sources, and analysis methods. Table 1 Main characteristics of the studies examining the relationship between circulating leptin, adiponectin levels and HCC Author, Year, Country Study design Study period the source of case group the source of Cancer-free control group Number Mean age Males BMI Sample source Measured indicators Detected method NOS score Abouzied, 2017, Egypt C – HCC Healthy controls 25/25 57.7/29.2 18/23 21.7/22.2 Serum Leptin ELISA 5 Aleksandrova, 2014, Europe N 2000–2006 HCC Healthy controls 125/250 60.1/60.1 85/171 28.1/26.9 Serum Leptin and AdipoQ ELISA 8 Ataseven, 2006, Yurkey C – HBV-related HCC HBV-related cirrhosis/ Healthy controls 22/23/25 59.8/45.5/37.1 15/11/11 – Serum Leptin ELISA 8 Bakir, 2017, Egypt S 03/2016–11/2016 HCV-related cirrhotic HCC HCV-related cirrhosis 50/40 53.2/50.7 29/25 24.5/26.1 Serum Leptin ELISA 5 Bastard, 2018, France N 03/2006–07/2016 Viral cirrhotic HCC Viral cirrhosis 56/96 59.8/58.9 34/61 25.6/25.8 Serum Leptin and AdipoQ ELISA 7 Chen, CL, 2014, Taiwan N 01/1999–12/2004 HBV-related HCC Chronic hepatitis B 187/374 52.4/52.2 154/311 – Plasma Leptin and AdipoQ ELISA 8 Chen, MJ, 2012, Taiwan C 01/2009–12/2009 Viral HCC Healthy controls 65/165 58.8/47.7 47/112 24.7/24.4 Serum AdipoQ RIA 6 Costantini,2013, Italy C – HCV-related HCC HCV-related cirrhosis / Chronic hepatitis C / Healthy controls 26/30/30/20 70.0/68/63.4/60.9 18/14/15/9 – Serum Leptin ELISA 8 Feder, 2019, Germany P 05/2012–05/2015 HCC Healthy controls 32/49 – – – Serum AdipoQ ELISA 7 Fukushima, 2010, Japan P 1993–2003 HCV-related HCC Chronic hepatitis C 9/27 53.0/51.3 5/11 – Serum Leptin (RIA) and HMW AdipoQ (ELISA) 8 Hamdy, 2015, Egypt S 01/2014–12/2014 HCV-related cirrhotic HCC HCV-related cirrhosis 61/29 52.3/52.3 51/21 33.7/36.7 Serum AdipoQ ELISA 8 Khattab, 2012, Egypt C 02/2009–01/2010 HCC Chronic hepatitis C / Healthy controls 147/147/320 43.9/41.6/42.9 114/115/201 24.9/25.1/25.3 Serum AdipoQ ECLI 6 Kotani, 2009, Japan N 1990–1999 HCC Healthy controls 59/334 63.5/62.7 – – Serum AdipoQ ELISA 5 Liu, CJ, 2009, Taiwan S 01/2002–10/2005 HBV-related HCC HBV-related cirrhosis / Chronic hepatitis B/ Healthy controls 120/40/120/116 50.7/50.3/30/53.8 100/29/63/67 – Serum AdipoQ ELISA 8 Liu, ZW, 2005, China C – HCV-related cirrhotic HCC HCV-related cirrhosis/ Chronic hepatitis C/ Healthy controls 2/10/30/30 59.5/53.7/41/39.4 2/6/17/18 23.0/22.7/23.0/23.1 Serum Leptin ELISA 8 Michikawa, 2013, Japan N 1993–2006 Viral HCC Chronic viral hepatitis 90/117 – 62/80 – plasma AdipoQ ELISA 8 Radwan, 2019, Egypt S – HCC Chronic hepatitis C 48/52 53.2/52.5 26/32 25.2/27.7 Serum AdipoQ ELISA 5 Sadik, 2012, Egypt C 01/2008–02/2009 HCV-related HCC HCV-related cirrhosis/ Healthy controls 69/36/21 59.1/53.0/55.8 43/23/13 28.0//27.1/29.1 Serum Leptin and AdipoQ ELISA 6 Sumie, 2011, Japan C 01/1997–10/2007 HCV-related HCC Chronic hepatitis C 97/97 67.4/61.2 67/67 22.5/23.1 Serum AdipoQ ELISA 7 Voumvouraki, 2011, Greece C – Viral cirrhotic HCC Viral cirrhosis/ Chronic hepatitis C / Healthy controls 38/34/44/60 62.0/60.0/53.0/−− 25/12/8/−− – Serum Leptin ELISA 8 Wang, 2003, Taiwan C 01/2000–12/2000 Viral cirrhotic HCC Viral cirrhosis/ Healthy controls 31/26/25 65.0/59.0/65.0 31/26/25 23.2/23.7/24.4 Serum Leptin RIA 6 P Cohort, S Cross-sectional, C Case-control, N Nested Case-control, HCC Hepatocellular carcinoma, HCV hepatitis C virus, HBV hepatitis B virus, ELISA Enzyme-linked immunosorbent assay, ECLI Electro-chemiluminescence immunoassay, RIA Radioimmunoassay, HMW AdipoQ High Molecular Weight Adiponectin, BMI body mass index, NOS Newcastle-Ottawa Scale Table 2 Main characteristics of the studies examining the relationship between leptin, adiponectin gene polymorphism and HCC Author, Year, Country Study design Case/control Number Matching variables SNP Samples source Genotyping methods Frequency of case genotype Frequency of control genotype NOS score Amer, 2017, Egypt C HCC/Healthy controls 150/100 age, sex and smoking rate rs7799039 (leptin gene) blood PCR-RFLP technique AA = 60; AG = 69; GG = 21; G allele =111; A allele =189 AA = 49; AG = 47; GG = 4; G allele =54; A allele =146 7 Zhang, 2018, China C HCC/Healthy controls 575/921 age and sex rs7799039 (leptin gene) blood SNPscan™ AA = 295; AG = 221; GG = 59; G allele = 339; A allele =811 AA = 505; AG = 360; GG = 56; G allele = 472; A allele =1370 7 Cai, 2013 China C HCC/Healthy controls 200/200 age and sex rs1501299 (adiponectin gene) blood DNA sequencing TT = 12; TG = 60; GG = 128; G allele = 316; T allele =84 TT = 39; TG = 69; GG = 92; G allele = 253; T allele =147 8 C Case-control, SNP single-nucleotide polymorphisms, PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism, NOS Newcastle-Ottawa Scale Table 3 Main characteristics of the studies examining the relationship between adiponectin, leptin levels and the prognosis of HCC Author, Year, Country Study design Study period Number Follow-up (months) Sample Measured indicators Detected method Cut-off value Survival analysis Source of HR Analytic method NOS score Siegel, 2014, USA P 2008–2012 140 8 Serum AdipoQ; Leptin RIA ≥13.05 μg/ml vs<13.05 μg/ml; ≥7.9 ng/ml vs<7.9 ng/ml OS Report M;U 7 Shen, 2016, USA P 2008–2014 135 84 Plasma AdipoQ ELISA ≥13.10 μg/ml vs<13.10 μg/ml OS Report M 7 Shin, 2014, Korea P 1996–2001 75 82.5 Cytoplasmic AdipoQ IHC Positive: > 0% of cells stained vs Negative: no cells stained OS Report M 6 Watanabe, 2011, Japan P 2006–2008 33 39 Plasma Leptin NA ≥5.0 ng/ml vs<5.0 ng/ml DFS Report M 7 Wang, 2014, Taiwan P 1999–2003 85 NA Cytoplasmic AdipoQ IHC Low: - ~ + vs High: ++ ~ +++a OS SC M 7 Wang, 2006, Taiwan P 1994–2003 68 31.7 Cytoplasmic Leptin IHC Low: - ~ + vs High: ++ ~ +++a OS SC M 6 ELISA Enzyme-linked immunosorbent assay, RIA Radioimmunoassay, IHC Immunohistochemistry, NA Not available, DFS Disease-free survival, OS Overall survival, SC Survival curves, U Univariate, M Multivariate. aSemiquantitative scoring system, NOS Newcastle-Ottawa Scale Quality assessment The Newcastle-Ottawa Scale was used to assess the quality of non-randomized controlled studies. The following three factors were considered: patient selection, comparability of study groups, and outcome evaluation. The highest score was 9 points, and studies with a score ≥ 7 were considered high-quality [14]. The above steps were independently cross-checked by two researchers (Zhang Lilong, Yuan Qixing), and all differences were handled by the senior author (Wang Weixing). Statistical analysis Stata 16.0 was used for statistical analysis. Dichotomous variables and continuous variables were compared by the odds ratio (OR) and standardized mean difference (SMD). The hazard ratio (HR) was calculated to assess the correlation between AdipoQ or leptin expression and the prognosis of HCC. In the case that the study only provided the Kaplan-Meier survival curve, used Engage Digitizer version 2.11 software to extract relevant values from the survival curve and calculate HR (95% CI) [15, 16]. For all analyses, the 95% confidence interval (CI) was used. P<0.05 was defined as statistically significant. The chi-squared test was calculated to evaluate the statistical heterogeneity between different studies. P > 0.1 and I2 < 50% indicated low heterogeneity where a fixed-effect model was used; otherwise, the random-effect model was adopted. Furthermore, a 2-stage dose-response meta-analysis was performed to explore the association between different categories of leptin, AdipoQ levels and HCC risk [17, 18]. 1) The fixed-effect nonlinear model was constructed based on the restrictive cubic spline function (Knot =3). 2) According to the results of the heterogeneity test and nonlinear correlation test, the corresponding model was adopted. Finally, for indicators with high heterogeneity, we conducted a sensitivity analysis by leaving one out method to check the robustness of the results and determine the source of heterogeneity. Besides, meta-regression analysis was performed to explore the potential sources of heterogeneity. For indicators containing more than 10 articles, we generated a funnel plot to visually check publication bias. Begg’s and Egger’s tests were also performed to quantitatively analyze publication bias, and P < 0.05 was considered statistically significant. If necessary, we verify the results of the publication bias by establishing a trim and fill funnel plot. Results Studies retrieved and characteristics In this meta-analysis, we identified 1068 potentially eligible records and screened their titles and abstracts for inclusion. After reading the full text of 78 records in detail, 30 studies met our inclusion criteria (Fig. 1). Although Ebrahim’s article fits the research topic, it is excluded because the full text is not available [19]. Twenty-one articles [20–40] (10 case-control, 5 nested case-control, 4 cross-sectional, and 2 cohort studies) evaluated the relationship between Leptin or AdipoQ levels and HCC risk, and main characteristics were summarized in Table 1. Three case-control studies [41–43] assessed the relationship between Leptin or AdipoQ gene polymorphism and HCC risk, and main characteristics were reported in Table 2. Six articles [44–49] analyzed the relationship between AdipoQ or leptin expression and the prognosis of HCC, and the main characteristics were summarized in Table 3. Quality assessment of the included studies using the Newcastle–Ottawa scale was shown in Tables 1, 2, 3, and the scores ranged from 5 to 8. Twenty articles were awarded 7 or 8 points, and considered as high-quality; Six studies were awarded 6 points and four studies were awarded 5 points, which were considered as moderate quality. Fig. 1 Flow diagram of the meta-analysis search process Association between circulating leptin levels and HCC risk Pooling data of 12 studies [20–25, 27, 29, 34, 37–39] with 1896 participants assessed the association between leptin levels and HCC risk. Heterogeneity analysis showed that significant heterogeneity was observed among the studies (I2 = 97.5%, P = 0.000), and the random-effect model was applied. The results showed that leptin levels were significantly higher in the HCC group than CFC group (SMD = 1.83, 95% CI (1.09, 2.58), P = 0.000) (Fig. 2). Subgroup analysis, according to the source of CFC group, showed HCC group had significantly higher leptin levels than the healthy control group (SMD = 4.32, 95% CI (2.41, 6.24), P = 0.000) and the cirrhosis group (SMD = 1.85, 95% CI (0.70, 3.01), P = 0.002), but there was no statistical difference when compared with the chronic hepatitis group (SMD = 0.94, 95% CI (− 0.1, 2.03), P = 0.090) (Fig. 3 and Table 4). We further conducted subgroup analysis by the source of case group, and the results showed HCV-related cirrhotic HCC had significantly higher leptin levels than HCV-related cirrhosis (SMD = 0.82, 95% CI (0.40, 1.24), P = 0. 0.000), whereas there was no difference in other subgroups (Table 4). Fig. 2 Forest plot of comparing circulating leptin levels between the HCC and cancer-free control group Fig. 3 Forest plot of the subgroup analyses concerning circulating leptin levels Table 4 Subgroup analysis of the association between circulating leptin levels and HCC risk Variable Included studies Test of association Test of heterogeneity SMD 95%CI P-value* Modal P-value I2 HCC vs Healthy controls  Overall [23–25, 30, 37, 40–42] 4.32 2.41, 6.24 0.000 RE 0.000 98.4%  HCC(unreported reason) vs Healthy controls [23, 24] 5.58 −5.11, 16.26 0.306 RE 0.000 98.8%  Viral cirrhotic HCC vs Healthy controls [37, 41, 42] 1.02 − 0.78, 2.79 0.263 RE 0.000 94.1%  HCV-related HCC vs Healthy controls [30, 37, 40] 8.87 − 1.08, 1.82 0.081 RE 0.000 98.7% HCC vs Cirrhosis  Overall [25–27, 30, 37, 40–42] 1.85 0.70, 3.01 0.002 RE 0.000 97.0%  HCV-related cirrhotic HCC vs HCV-related cirrhosis [26, 37] 0.82 0.40, 1.24 0.000 FE 0.145 53.0%  HCV-related HCC vs HCV-related cirrhosis [30, 40] 8.71 −3.84, 21.25 0.174 RE 0.000 99.2%  Viral cirrhotic HCC vs Viral cirrhosis [27, 41, 42] 0.13 −0.11,0.37 0.302 FE 0.591 0 HCC vs Chronic hepatitis  Overall [28, 30, 32, 37, 41] 0.94 −0.15, 2.03 0.090 RE 0.000 94.9%  HCV-related HCC vs Chronic hepatitis C [30, 32, 37] 1.63 −1.39, 4.65 0.290 RE 0.000 96.0%  Viral cirrhotic HCC vs Chronic hepatitis C [37, 41] −0.10 − 0.51,0.32 0.643 FE 0.561 0 Ethnicity  Asian [25, 28, 32, 37, 42] 0.10 −0.50, 0.70 0.751 RE 0.000 85.6%  Caucasian [24, 27, 30, 41] 0.58 −0.06, 1.22 0.077 RE 0.000 93.3%  African [23, 26, 40] 9.36 −1.27, 19.99 0.084 RE 0.000 99.3% Sample size  < 100 [23, 25, 26, 32, 37, 42] 1.57 0.22, 2.91 0.022 RE 0.000 95.8%  ≥ 100 [24, 27, 28, 30, 40, 41] 2.23 1.21, 3.26 0.000 RE 0.000 98.4% Mean age  < 60 [23, 25–28, 32, 37, 40] 2.87 1.57, 4.17 0.000 RE 0.000 98.2%  ≥ 60 [24, 30, 41, 42] 0.76 0.03, 1.49 0.040 RE 0.000 93.7% Study design  Case-control [23, 25, 30, 37, 40, 41] 3.81 1.83, 5.79 0.000 RE 0.000 97.5%  Nested Case-control [24, 27, 28] 0.14 0.01, 0.26 0.035 FE 0.777 0.0% Assay method  ELISA [23–28, 30, 37, 40, 41] 2.13 1.27, 2.99 0.000 RE 0.000 97.9%  RIA [32, 42] 0.79 0.39, 1.19 0.000 FE 0.570 0.0% Alanine aminotransferase  < 70 U/L [23, 26, 28, 32, 37, 40] 4.42 2.26, 6.50 0.000 RE 0.000 98.6%  ≥ 70 U/L [25, 27, 30, 41, 42] 0.43 −0.38, 1.23 0.296 RE 0.000 94.4% Albumin  < 3.5 g/dl [25, 26, 30, 40, 42] 3.47 1.28, 5.66 0.002 RE 0.000 98.7%  ≥ 3.5 g/dl [27, 28, 32, 41] 0.12 −0.02, 0.26 0.091 FE 0.633 0.0% RE Random-effects model, FE Fixed-effects model, HCC Hepatocellular carcinoma, HCV hepatitis C virus *Statistically significant results were shown in bold In addition, we also performed other subgroup analyses and the results were shown in Table 4. Stratification by ethnicity showed no significant difference in the HCC group and CFC group in Asian (SMD = 0.10, 95% CI (− 0.50, 0.70), P = 0.751), Caucasian (SMD = 0.58, 95% CI (− 0.06, 1.22), P = 0.077) and African population (SMD = 9.36, 95% CI (− 1.27, 19.99), P = 0.084). Stratification by sample size showed HCC group had significantly higher leptin levels than CFC group in both small (n < 100) sample numbers (SMD = 1.57, 95% CI (0.22, 2.91), P = 0.022) and large (n ≥ 100) sample numbers (SMD = 2.23, 95% CI (1.21, 3.26), P = 0.000). Stratification by mean age showed HCC group had significantly higher leptin levels than CFC group in both “< 60” (SMD = 2.87, 95% CI (1.57, 4.17), P = 0.000) and “≥ 60” (SMD = 0.76, 95% CI (0.03, 1.49), P = 0.040). Stratification by study design showed HCC group had significantly higher leptin levels than CFC group in both case-control studies (SMD = 3.81, 95% CI (1.83, 5.79), P = 0.000) and nested case-control studies (SMD = 0.14, 95% CI (0.01, 0.26), P = 0.035). Stratification by assay method revealed the HCC group had significantly higher leptin levels than the CFC group by both “ELISA” (SMD = 2.13, 95% CI (1.27, 2.99), P = 0.000) and “RIA” (SMD = 0.79, 95% CI (0.39, 1.19), P = 0.000). Stratification by Alanine aminotransferase (ALT) levels of HCC patients showed HCC group had significantly higher leptin levels than CFC group in “< 70 U/L” (SMD = 4.42, 95% CI (2.26, 6.50), P = 0.000), but not in the “≥ 70 U/L” (SMD = 0.43, 95% CI (− 0.38, 1.23), P = 0.296). Stratification by albumin levels of HCC patients showed HCC group had significantly higher leptin levels than CFC group in “< 3.5 g/dl” (SMD = 3.47, 95% CI (1.28, 5.66), P = 0.002), but not in the “≥ 3.5 g/dl” (SMD = 0.12, 95% CI (− 0.02, 0.26), P = 0.091). Meta-regression analysis showed that only the ethnicity (P = 0.004), not the source of control (P = 0.242) and case (P = 0.185), sample size (P = 0.735), mean age (P = 0.420), study design (P = 0.344), assay method (P = 0.606), ALT (P = 0.172) and albumin (P = 0.853), had significant impacts on the heterogeneity in the meta-analysis. To assess the impacts of each study on the overall meta-analysis, we carried out sensitivity analysis using the leave-one-out method. No substantial change of data on leptin levels was observed. Therefore, the results of our meta-analysis were relatively stable and credible (Fig. 4). Fig. 4 Sensitivity analysis of comparing circulating leptin levels between the HCC and cancer-free control group A funnel plot representing SMDs of the leptin levels in the HCC group compared to the CFC group was used to evaluate publication bias. Through the visual inspection of the funnel plot, there was obvious asymmetry that indicated a possibility of publication bias (Fig. 5), which were supported by Begg’s tests (P = 0.034) and Egger’s tests (P = 0.025). Therefore, further verification by trim and fill funnel plot was employed to adjust for the potential publication bias. However, the pooled data regarding leptin that had been significant before the adjustment with the “trim and fill” method remained significant after the adjustment (SMD = 3.486, 95% CI (0.937–6.035), P < 0.05), indicating that this publication bias did not affect the pooled estimates. Fig. 5 Funnel plot of comparing circulating leptin levels between the HCC and cancer-free control group Association between circulating AdipoQ levels and HCC risk Pooling data of 13 studies [21, 24–26, 28, 30–33, 35–37, 40] with 2092 participants were evaluated on the association between AdipoQ levels and HCC risk. Heterogeneity analysis showed significant heterogeneity among the studies (I2 = 98.2%, P = 0.000), and the random-effect model was applied. There was no statistical difference in HCC and CFC group on AdipoQ levels(SMD = 0.24, 95% CI (− 0.35, 0.82), P = 0.430) (Fig. 6). Fig. 6 Forest plot of comparing circulating adiponectin levels between the HCC and cancer-free control group Subgroup analysis, according to the source of CFC group, showed HCC group had significantly higher AdipoQ levels than the healthy control group (SMD = 1.57, 95% CI (0.37, 2.76), P = 0.010), but there was no statistical difference compared with the chronic hepatitis group (SMD = 0.10, 95% CI (− 0.80, 1.00), P = 0.826) and the cirrhosis group (SMD = − 0.51, 95% CI (− 1.30, 0.29), P = 0.213) (Fig. 7 and Table 5). We further conducted subgroup analysis by the source of case group, and the results showed viral HCC had significantly higher AdipoQ levels than healthy controls (SMD = 1.11, 95% CI (0.44, 1.78), P = 0. 0.001), and HCV-related HCC had significantly lower AdipoQ levels than HCV-related cirrhosis (SMD = − 1.22, 95% CI (− 1.54, − 0.90), P = 0. 0.000), whereas there was no difference in other subgroups (Table 5). Fig. 7 Forest plot of the subgroup analyses concerning circulating adiponectin levels Table 5 Subgroup analysis of the association between circulating adiponectin levels and HCC risk Variable Included studies Test of association Test of heterogeneity SMD 95%CI P-value* Modal P-value I2 HCC vs Healthy controls  Overall [24, 29, 31, 34–36, 40] 1.57 0.37, 2.76 0.010 RE 0.000 99.0%  HCC(unreported reason) vs Healthy controls [24, 31, 34, 35] 1.88 −0.31, 4.08 0.092 RE 0.000 99.5%  Viral HCC vs Healthy controls [29, 36, 40] 1.11 0.44, 1.78 0.001 RE 0.000 90.8% HCC vs Cirrhosis  Overall [27, 33, 36, 40] −0.51 −1.30, 0.29 0.213 RE 0.000 93.9%  Viral cirrhotic HCC vs Viral cirrhosis [27, 33] −0.37 −1.80, 1.05 0.607 RE 0.000 95.9%  HCV-related HCC vs HCV-related cirrhosis [33, 40] −1.22 −1.54, −0.90 0.000 FE 0.531 0.0% HCC vs Chronic hepatitis  Overall [28, 34, 36, 38, 39, 43] 0.10 −0.80, 1.00 0.826 RE 0.000 98.4%  HCC(unreported causes) vs Chronic hepatitis C [34, 39] − 0.48 −5.71, 4.75 0.857 RE 0.000 99.6%  HCV-related HCC vs Chronic hepatitis C [28, 43] 0.08 −0.22,0.38 0.599 RE 0.068 70.0%  Viral HCC vs Chronic viral hepatitis [28, 36, 38, 43] 0.35 −0.08, 0.78 0.108 RE 0.000 91.8% Ethnicity  Asian [28, 29, 35, 36, 38, 43] 0.31 0.02, 0.61 0.036 RE 0.000 88.3%  Caucasian [24, 27, 31] 0.73 0.11, 1.35 0.022 RE 0.000 90.3%  African [33, 34, 39, 40] −0.32 −2.93, 2.29 0.811 RE 0.000 99.5% Sample size  < 200 [27, 31, 33, 39, 40, 43] 0.76 0.03, 1.50 0.042 RE 0.000 98.5%  ≥ 200 [24, 28, 29, 34–36, 38] −0.40 −1.34, 0.54 0.403 RE 0.000 97.1% Mean age  < 60 [27–29, 33, 34, 36, 39, 40] 0.10 −0.85, 1.05 0.833 RE 0.000 98.8%  ≥ 60 [24, 35, 43] 0.13 −0.14, 0.39 0.362 RE 0.037 69.7% Study design  Nested Case-control [24, 27, 28, 35, 38] 0.25 0.14, 0.36 0.000 EE 0.585 0.0%  Case-control [29, 34, 40, 43] 0.84 −0.74, 2.12 0.298 RE 0.000 99.2%  Cross-sectional [33, 36, 39] −1.10 −3.46, 1.26 0.361 RE 0.000 99.0% Sample source  Serum [24, 27, 29, 31, 33–36, 39, 40, 43] 0.23 −0.51, 0.97 0.540 RE 0.000 98.5%  Plasma [28, 38] 0.23 0.08, 0.38 0.003 FE 0.795 0.0% Assay method  ELISA [24, 27, 28, 31, 33, 35, 36, 38–40, 43] −0.03 −0.45, 0.40 0.901 RE 0.000 95.7%  Non-ELISA [29, 34] 1.75 −0.75, 4.26 0.170 RE 0.000 99.4% Alanine aminotransferase  < 70 U/L [28, 33, 36, 40, 43] 0.00 −0.53, 0.53 0.992 RE 0.000 94.8%  ≥ 70 U/L [27, 34, 39] 0.08 −2.96, 3.12 0.958 RE 0.000 99.5% Albumin  < 3.5 g/dl [33, 34, 40] 0.62 −1.98, 3.22 0.639 RE 0.000 98.5%  ≥ 3.5 g/dl [27, 28] 0.24 0.09,0.40 0.002 RE 0.000 99.4% RE Random-effects model, FE Fixed-effects model, HCC Hepatocellular carcinoma, HCV hepatitis C virus *Statistically significant results were shown in bold Subgroup analysis, according to the molecular-weight of AdipoQ, showed no significant difference about high-molecular-weight AdipoQ (SMD = − 0.01, 95% CI (− 0.20, 0.18), P = 0.911) and non-high-molecular-weight AdipoQ (SMD = 0.28, 95% CI (− 0.06, 0.62), P = 0.103) levels in the HCC group and CFC group (Fig. 8). In addition, we also performed other subgroup analysis and the results were shown in Table 5. Stratification by ethnicity showed HCC group had significantly higher AdipoQ levels than CFC group in Asian (SMD = 0.31, 95% CI (0.02, 0.61), P = 0.036) and Caucasian population (SMD = 0.73, 95% CI (0.11, 1.35), P = 0.022), but not in African population (SMD = − 0.32, 95% CI (− 2.93, 2.29), P = 0.811). Stratification by sample size showed HCC group had significantly higher AdipoQ levels than CFC group in small (n < 200) sample numbers (SMD = 0.76, 95% CI (0.03, 1.50), P = 0.042), but not in large (n ≥ 200) sample numbers (SMD = − 0.40, 95% CI (− 1.34, 0.54), P = 0.403). Stratification by mean age showed no significant difference in the HCC group and CFC group in both “< 60” (SMD = 0.10, 95% CI (− 0.85, 1.05), P = 0.833) and “≥ 60” (SMD = 0.13, 95% CI (− 0.14, 0.39), P = 0.362). Stratification by study design showed HCC group had significantly higher AdipoQ levels than CFC group in nested case-control studies (SMD = 0.25, 95% CI (0.14, 0.36), P = 0.000), but not in case-control studies (SMD = 0.84, 95% CI (− 0.74, 2.12), P = 0.298), and cross-sectional studies (SMD = − 1.10, 95% CI (− 3.46, 1.26), P = 0.361). Stratification by the sample source revealed HCC group had significantly higher AdipoQ levels than CFC group in the source of plasma (SMD = 0.23, 95% CI (0.08, 0.38), P = 0.003), but not in the source of serum (SMD = 0.23, 95% CI (− 0.51, 0.97), P = 0.540). Stratification by assay method revealed no significant difference in the HCC group and CFC group by both “ELISA” (SMD = − 0.03, 95% CI (− 0.45, 0.40), P = 0.901) and “Non-ELISA” (SMD = 1.75, 95% CI (− 0.75, 4.26), P = 0.170). Stratification by ALT levels of HCC patients showed no significant difference in the HCC group and CFC group in both “< 70 U/L” (SMD = 0.00, 95% CI (− 0.53, 0.53), P = 0.992) and “≥ 70 U/L” (SMD = 0.08, 95% CI (− 2.96, 3.12), P = 0.958). Stratification by albumin levels of HCC patients showed HCC group had significantly higher AdipoQ levels than CFC group in “≥ 3.5 g/dl” (SMD = 0.24, 95% CI (0.09,0.40), P = 0.002), but not in the “< 3.5 g/dl” (SMD = 0.62, 95% CI (− 1.98, 3.22), P = 0.639). In addition, we also found that AdipoQ levels in HCC patients were not related to gender(man vs woman: SMD = − 0.29, 95% CI (− 0.69, 0.11), P = 0.153) and vascular invasion (present vs absent: SMD = 0.19, 95% CI (− 0.11, 0.49), P = 0.208). Fig. 8 Forest plot of the subgroup analyses based on the molecular-weight of adiponectin between the HCC and cancer-free control group Khattab et al. [30] found that AdipoQ levels in HCC with the size of nodules≥5 cm were significantly higher than<5 cm (24.2 ± 2.1 vs 20.8 ± 3.8, P = 0.009), whereas, AdipoQ levels were not related to TNM stages, number of nodules and lymph node metastasis. Feder et al. [27] discovered that AdipoQ levels were no statistical difference in HCC and colorectal liver metastases patients, and negatively related to steatosis grade, but not correlate with inflammation or fibrosis score. Sadik et al.35 reported that AdipoQ levels of cirrhotic HCC were significantly higher than the noncirrhotic HCC group, whereas leptin was not. Meta-regression analysis showed that the source of control (P = 0.150) and case (P = 0.579), ethnicity (P = 0.338), sample size (P = 0.140), mean age (P = 0.540), study design (P = 0.283), assay method (P = 0.092), source of sample (P = 0.993), ALT(P = 0.544) and albumin (P = 0.575) had no significant effects on the heterogeneity in the meta-analysis. We also carried out sensitivity analysis using the leave-one-out method, and no substantial change of data on AdipoQ levels were observed, therefore, the results of our meta-analysis were relatively stable and credible (Fig. 9). Fig. 9 Sensitivity analysis of comparing circulating adiponectin levels between the HCC and cancer-free control group A funnel plot representing SMDs of the AdipoQ levels in the HCC group compared to the CFC group was used to assess publication bias. Through the visual inspection of the funnel plot, there was obvious asymmetry that indicated a possibility of publication bias (Fig. 10), which were not supported by the Begg’s tests (P = 0.300) and Egger’s tests (P = 0.142); therefore, further verification by trim and fill funnel plot was employed to adjust for the potential publication bias. The result of the “trim and fill” method revealed that no trimming was performed and the data was unchanged, suggesting that there was no significant publication bias. Fig. 10 Funnel plot of comparing circulating adiponectin levels between the HCC and cancer-free control group Association between leptin, AdipoQ gene polymorphism and HCC risk Pooling data from 2 studies [41, 43] with 1746 participants evaluated the association between leptin rs7799039 and HCC risk. In the allele model analysis, the G allele was significantly associated with an increased risk in HCC (G vs A: OR = 1.28, 95% CI (1.10, 1.48), P = 0.002). In the codominant model analysis, the GG genotype was associated with a 2.03-fold elevated risk in HCC (GG vs AA: OR = 2.03, 95% CI (1.41, 2.93), P = 0.000), whereas the AG genotype was not (AG vs AA: OR = 1.07, 95% CI (0.87, 1.31), P = 0.505). In the recessive model analysis, the GG genotype was associated with a 1.97-fold increased risk in HCC (GG vs AA+AG: OR = 1.97, 95% CI (1.38, 2.82), P = 0.000). However, in the overdominant and dominant model analysis, the AG and AG + GG genotypes were no significantly associated with the risk in HCC (AG vs AA+GG: OR = 0.97, 95% CI (0.80, 1.18), P = 0.770; AG + GG vs AA: OR = 1.19, 95% CI (0.98, 1.44), P = 0.078). There was no significant heterogeneity in the above results (Fig. 11). Fig. 11 Forest plot for the association between leptin rs7799039 and HCC risk As for AdipoQ, Cai et al. [42] found that the AdipoQ rs1501299 was associated with the increased susceptibility to HCC, and the additive model showed that the GT and GG genotypes were significantly associated with an increased risk in HCC (GT vs TT: OR = 2.83, 95% CI (1.36, 5.89), P = 0.006; GG vs TT: OR = 4.52, 95% CI (2.25, 9.11), P = 0.001). In the dominant model analysis, the GG + GT genotypes were associated with a 3.8-fold elevated risk in HCC(GG + GT vs TT: OR = 3.795, 95% CI (1.92, 7.49), P = 0.001). However, the rs266729, rs822395, rs822396, and rs2241766 were not significantly associated with HCC. Unfortunately, we just retrieved one study that evaluated the association of AdipoQ gene polymorphism with HCC, so we failed to perform a related meta-analysis. Dose-response of circulating AdipoQ, leptin levels and HCC risk Pooling data from 4 studies [21, 25, 32, 35] with 1507 participants showed that there was a linear dose-response relationship between circulating AdipoQ levels and HCC risk (Pnon-linearity = 0.233). We defined the increment in 1 μg/ml AdipoQ levels as a unit to show the trend more clearly. The trends were significant for increasing HCC risk per one unit increase of AdipoQ (OR = 1.066, 95% CI (1.03, 1.11), P = 0.001; Fig. 12), without significant heterogeneity (Pheterogeneity = 0.338). Fig. 12 Dose-response associations of circulating adiponectin levels and HCC risk As for leptin, Aleksandrova et al. [21] and Chen et al. [25] both confirmed that circulating leptin levels were no significant dose-response trend in the development of HCC. Unfortunately, we only found two studies, and unable to perform a meta-analysis. Association between AdipoQ, leptin and survival in HCC Pooling data of 4 studies [44–46, 48] with 435 participants analyzed the association between AdipoQ expression and survival in HCC. Heterogeneity analysis showed that no heterogeneity was observed among the studies (I2 = 0%, P = 0.660), the fixed-effect model was applied. The results showed that high/positive expression of AdipoQ was significantly related to lower overall survival (OS) in HCC patients (HR = 1.70, 95% CI (1.22, 2.37), P = 0.002; Fig. 13). Fig. 13 Forest plot of the relationship between adiponectin, leptin expression and survival in HCC Pooling data of 3 studies [44, 47, 49] with 241 participants measured the association between leptin expression and prognosis for HCC. Heterogeneity analysis showed that significant heterogeneity was observed among the studies (I2 = 66.0%, P = 0.053), the random-effect model was applied. The results showed that high/positive expression of leptin was not significantly associated with prognosis in HCC patients (HR = 0.92, 95% CI (0.53, 1.59), P = 0.766; Fig. 13). Discussion In the past two decades, many studies have explored the relationship between the abnormal expression of leptin and AdipoQ and various obesity-related cancers. In 2016, a meta-analysis of 107 articles [50] was conducted to investigate AdipoQ levels in various malignancies and found that AdipoQ levels in certain cancers (including acute leukemia, multiple myeloma, breast cancer, colorectal cancer, and uterine cancer, endometrial cancer, prostate cancer, thyroid cancer, tongue cancer, and gastroesophageal cancer) were significantly reduced, while HCC was significantly higher than the CFC group. However, the meta-analysis involved only 7 articles on HCC. Song et al. [51] analyzed 9 Chinese and English studies and got the same result. Our results showed that the AdipoQ levels of HCC patients were significantly higher than that of the healthy control group, but there is no significant difference in the AdipoQ levels compared with the CFC group. So far, no meta-analysis on leptin and liver cancer risk has been performed. Our results indicated that the leptin levels of liver cancer patients were significantly higher than that of the CFC group, healthy control group, and liver cirrhosis group. In addition, comparing the different sources of the HCC group and the CFC group, the results were different. Therefore, we can conclude that AdipoQ and leptin levels in patients with chronic hepatitis and cirrhosis have changed compared with healthy controls, which is consistent with Buechler’s conclusion [13]. Because the patients included in this study were recruited from different backgrounds of gender, race, other demographic parameters, and the overall health of the individual, a high degree of heterogeneity was observed in this meta-analysis, and the study results should be interpreted with caution. We performed meta-regression, subgroup analysis, and sensitivity analysis to determine the source of heterogeneity. The meta-regression results of leptin indicated that the heterogeneity came from race, and the subgroup analysis showed that the heterogeneity was related to the source of the control group, study design, assay method, and baseline albumin levels. In the pooled analysis of AdipoQ, the source of heterogeneity was not found by the meta-regression, and the heterogeneity was linked to the control group, study design, average age, and sample source by the subgroup analyses. Many single nucleotide polymorphisms have been found in the leptin gene. The earliest is the LEP rs7799039 polymorphism, a SNP identified in the 50 untranslated regions of the leptin gene [52]. Research has been conducted on the tumor and recommendations have been made. It may affect the transcription levels and leptin expression [53]. Some previous meta-analysis showed that LEP rs7799039 polymorphism confers cancer risk [54–56]. However, no meta-analysis was performed to explore the association between LEP rs7799039 gene polymorphism and HCC risk. In this study, we found that the LEP rs7799039 polymorphism was related to the susceptibility to HCC. Unfortunately, too few studies were included, and conclusions should be confirmed by higher-quality studies. Through dose-response, we can more clearly explore the relationship between AdipoQ and leptin and liver cancer risk. In 2019, Yoon et al. [57] found that AdipoQ levels were significantly associated with a decreased risk of breast cancer, colorectal cancer, and endometrial cancer, while leptin was associated with an increased risk of cancers such as endometrial cancer and kidney cancer. However, our results indicated that the increase in AdipoQ levels was of great significance for increasing the risk of HCC. There were only 2 dose-response studies between leptin and HCC risk, so the meta-analysis was abandoned. Leptin and AdipoQ may not only be closely related to the occurrence of cancer, but closely associated with the prognosis of cancer. Our findings indicated that the high/positive expression of AdipoQ in liver cancer patients was significantly associated with decreased OS, which is similar to a meta-analysis of 10 studies, which revealed that increased AdipoQ expression is associated with poor prognosis in cancer patients (including HCC patients) [58]. It is worth noting that in this meta-analysis, the high/positive expression of leptin was not significantly associated with the prognosis of HCC patients. High levels of leptin may play an important role in promoting cancer cell migration, proliferation, survival, and angiogenesis [59, 60]. This is achieved by activating the Janus kinase/signal transducer and activator of transcription, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, and extracellular signal-regulated kinase signaling pathway [61, 62], which is considered related to oncogenes [63, 64].. Leptin can also promote the development of liver fibrosis, steatosis, and pro-inflammatory [4, 65]. In addition, Mittenbuhler et al. the leptin signal is found in obesity as the promoter of HCC [66]. Many studies have found that AdipoQ has significant anti-proliferative, anti-cancer activity, and anti-inflammatory effects [67]. Nazmy et al. have found that the tumor suppressor activity of AdipoQ can provide the body with more anti-HCC effects by preventing the decrease of p53 expression, the reactivation of TNF-related apoptosis-inducing ligand signals, and the induction of apoptosis pathways [68]. Al-Gayyar et al. revealed that AdipoQ can completely prevent the increase of HCC-induced sulfatase-2, improve HCC-induced tumor invasion markers, matrix metalloproteinase 9, syndecan-1 and fibroblast growth Factor-2 induced by HCC, decrease the expression of NF-κB and tumor necrosis factor α (TNF-α) induced by HCC, to achieve liver protection [69]. Manieri’s research shows that AdipoQ can activate two proteins in hepatocytes, p38α and AMP-activated protein kinase, which can prevent cell proliferation and damage tumor growth [70]. Our finding that elevated AdipoQ is associated with a high risk of liver cancer and poor prognosis seems to be contradictory to the above view. Some mechanisms have been proposed to resolve this contradiction. 1) AdipoQ resistance: Even if AdipoQ is expressed in large amounts, it may not be able to prevent poor prognosis caused by the down-regulation of AdipoQ receptors or dysfunction of AdipoQ signaling pathway. Many HCC patients suffer from cirrhosis or fibrosis, both of which are related to the down-regulation of AdipoQ receptors in the liver and the decrease of AdipoQ clearance rate, which leads to AdipoQ resistance state [71]. Similarly, the expression of AdipoQ could have been enhanced to compensate for the progression of HCC, but due to the overall deterioration of the patient’s physical condition, higher AdipoQ levels were ineffective. 2) AdipoQ stimulates AKT-mediated activation of cancer cells, which is an important predictor of low survival rate [48, 72]. Some limitations should be considered in this meta-analysis. First, due to the high degree of heterogeneity, some results should be interpreted with caution. Secondly, few studies have been conducted to explore the correlation between leptin, AdipoQ gene polymorphism and HCC risk. The results of LEP rs7799039 gene polymorphism and HCC risk need more confirmation. Third, we partially extracted HR from the survival curve of the original article, which may introduce some small errors. Finally, almost all studies in the meta-analysis measured leptin and AdipoQ levels only once, and did not show long-term changes in the course of HCC. Conclusions This study showed that high leptin levels were associated with a higher risk of HCC, which may be a useful biomarker for early detection of HCC. The AdipoQ levels were directly proportional to the risk of HCC with a linear dose-response relationship and were associated with poor prognosis, which may be a potential biomarker for evaluating the prognosis of HCC. Abbreviations HCCHepatocellular carcinoma HCVHepatitis C virus HBVHepatitis B virus CFCCancer-free control AdipoQAdiponectin SMDStandardized mean difference OROdds ratio HRHazard ratio CIConfidence interval NOSNewcastle-Ottawa Scale ALTAlanine aminotransferase ELISAEnzyme-linked immunosorbent assay RIARadioimmunoassay OSOverall survival Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wenhong Deng and Weixing Wang contributed equally to this work. The authors thank all the medical staff who contributed to the maintenance of the medical record database. Authors’ contributions ZL and WW conceived and designed the study. ZL, YQ, and CD were responsible for the collection and assembly of data, data analysis, and interpretation. ZL was involved in writing the manuscript. LM and DW revised the manuscript. All the work was performed under DW and WW instruction. All authors read and approved the final manuscript. Funding The authors received no specific funding for this work. Availability of data and materials The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. ==== Refs References 1. Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2018 68 6 394 424 10.3322/caac.21492 30207593 2. Liang H Xiong Z Li R Hu K Cao M Yang J BDH2 is disintegrated in hepatocellular carcinoma and acts as a tumor suppressor regulating cell apoptosis and autophagy J Cancer 2019 10 16 3735 3745 10.7150/jca.32022 31333791 3. Ueno Y Sollano JD Farrell GC Prevention of hepatocellular carcinoma complicating chronic hepatitis C J Gastroenterol Hepatol 2009 24 4 531 536 10.1111/j.1440-1746.2009.05814.x 19368633 4. Wang SN Lee KT Ker CG Leptin in hepatocellular carcinoma World J Gastroenterol 2010 16 46 5801 5809 10.3748/wjg.v16.i46.5801 21155000 5. Buechler C Wanninger J Neumeier M Adiponectin, a key adipokine in obesity related liver diseases World J Gastroenterol 2011 17 23 2801 2811 21734787 6. Stolzenberg-Solomon RZ Newton CC Silverman DT Pollak M Nogueira LM Weinstein SJ Circulating leptin and risk of pancreatic cancer: a pooled analysis from 3 cohorts Am J Epidemiol 2015 182 3 187 197 10.1093/aje/kwv041 26085045 7. Arita Y Kihara S Ouchi N Takahashi M Maeda K Miyagawa J Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochem Biophys Res Commun 1999 257 1 79 83 10.1006/bbrc.1999.0255 10092513 8. Wang ZV Scherer PE Adiponectin, the past two decades J Mol Cell Biol 2016 8 2 93 100 10.1093/jmcb/mjw011 26993047 9. Adolph TE, Grander C, Grabherr F, Tilg H. Adipokines and non-alcoholic fatty liver disease: multiple interactions. Int J Mol Sci. 2017;18(8). 10. Kamada Y Matsumoto H Tamura S Fukushima J Kiso S Fukui K Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model J Hepatol 2007 47 4 556 564 10.1016/j.jhep.2007.03.020 17459514 11. Saxena NK Fu PP Nagalingam A Wang J Handy J Cohen C Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma Gastroenterology 2010 139 5 1762 1773, 1773.e1761–1765 10.1053/j.gastro.2010.07.001 20637208 12. Wieser V Moschen AR Tilg H Adipocytokines and hepatocellular carcinoma Dig Dis 2012 30 5 508 513 10.1159/000341702 23108307 13. Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in liver cirrhosis. Int J Mol Sci. 2017;18(7). 14. Stroup DF Berlin JA Morton SC Olkin I Williamson GD Rennie D Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group JAMA 2000 283 15 2008 2012 10.1001/jama.283.15.2008 10789670 15. Parmar MK Torri V Stewart L Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints Stat Med 1998 17 24 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8 9921604 16. Tierney JF Stewart LA Ghersi D Burdett S Sydes MR Practical methods for incorporating summary time-to-event data into meta-analysis Trials 2007 8 16 10.1186/1745-6215-8-16 17555582 17. Guo J Astrup A Lovegrove JA Gijsbers L Givens DI Soedamah-Muthu SS Milk and dairy consumption and risk of cardiovascular diseases and all-cause mortality: dose-response meta-analysis of prospective cohort studies Eur J Epidemiol 2017 32 4 269 287 10.1007/s10654-017-0243-1 28374228 18. Greenland S Longnecker MP Methods for trend estimation from summarized dose-response data, with applications to meta-analysis Am J Epidemiol 1992 135 11 1301 1309 10.1093/oxfordjournals.aje.a116237 1626547 19. Ebrahim MA, Shams MEE, Al-Gayyar MMH, El-Shishtawy MM. Circulating adiponectin in hepatocellular carcinoma: a possible risk factor for development and progression. Eur J Clin Med Oncol. 2012;4(4). 20. Abouzied MM Nazmy MH Mohamed RM Fawzy MA Eltahir HM Diagnostic utility of leptin and insulin-like growth factor binding protein-2 in hepatocellular carcinoma of diabetic and non-diabetic Egyptian patients Trop J Pharm Res 2017 16 1 211 218 10.4314/tjpr.v16i1.28 21. Aleksandrova K Boeing H Nothlings U Jenab M Fedirko V Kaaks R Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer Hepatology 2014 60 3 858 871 10.1002/hep.27016 24443059 22. Bakir AS Al Swaff R Rasmy HS Mandoor A Circulating leptin in patients with liver cirrhosis and hepatocellular carcinoma Res J Pharm, Biol Chem Sci 2017 8 3 341 350 23. Bastard JP Fellahi S Audureau E Layese R Roudot-Thoraval F Cagnot C Elevated adiponectin and sTNFRII serum levels can predict progression to hepatocellular carcinoma in patients with compensated HCV1 cirrhosis Eur Cytokine Netw 2018 29 3 112 120 10.1684/ecn.2018.0413 30547888 24. Chen CL Yang WS Yang HI Chen CF You SL Wang LY Plasma adipokines and risk of hepatocellular carcinoma in chronic hepatitis B virus-infected carriers: a prospective study in Taiwan Cancer Epidemiol Biomark Prev 2014 23 8 1659 1671 10.1158/1055-9965.EPI-14-0161 25. Chen MJ Yeh YT Lee KT Tsai CJ Lee HH Wang SN The promoting effect of adiponectin in hepatocellular carcinoma J Surg Oncol 2012 106 2 181 187 10.1002/jso.23059 22287480 26. Costantini S Capone F Maio P Guerriero E Colonna G Izzo F Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma Oncol Rep 2013 29 6 2163 2168 10.3892/or.2013.2378 23564159 27. Feder S Kandulski A Schacherer D Weiss TS Buechler C Serum adiponectin levels do not distinguish primary from metastatic liver tumors Anticancer Res 2020 40 1 143 151 10.21873/anticanres.13935 31892562 28. Fukushima N Kuromatsu R Arinaga-Hino T Ando E Takata A Sumie S Adipocytokine involvement in hepatocellular carcinoma after sustained response to interferon for chronic hepatitis C Hepatol Res 2010 40 9 911 922 10.1111/j.1872-034X.2010.00699.x 20887596 29. Hamdy K Al Swaff R Hussein HA Gamal M Assessment of serum adiponectin in Egyptian patients with HCV-related cirrhosis and hepatocellular carcinoma J Endocrinol Investig 2015 38 11 1225 1231 10.1007/s40618-015-0379-3 26359143 30. Khattab MA Eslam M Mousa YI Ela-Adawy N Fathy S Shatat M Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma Ann Hepatol 2012 11 4 487 494 10.1016/S1665-2681(19)31462-0 22700630 31. Liu CJ Chen PJ Lai MY Liu CH Chen CL Kao JH High serum adiponectin correlates with advanced liver disease in patients with chronic hepatitis B virus infection Hepatol Int 2009 3 2 364 370 10.1007/s12072-008-9111-0 19669362 32. Liu ZW Zhang N Han QY Zeng JT Chu YL Qiu JM Correlation of serum leptin levels with anthropometric and metabolic parameters and biochemical liver function in Chinese patients with chronic hepatitis C virus infection World J Gastroenterol 2005 11 22 3357 3362 10.3748/wjg.v11.i22.3357 15948239 33. Michikawa T Inoue M Sawada N Sasazuki S Tanaka Y Iwasaki M Plasma levels of adiponectin and primary liver cancer risk in middle-aged Japanese adults with hepatitis virus infection: a nested case-control study Cancer Epidemiol Biomark Prev 2013 22 12 2250 2257 10.1158/1055-9965.EPI-13-0363 34. Radwan HA Hamed EH Saleh OM Significance of serum adiponectin and insulin resistance levels in diagnosis of Egyptian patients with chronic liver disease and HCC Asian Pac J Cancer Prev 2019 20 6 1833 1839 10.31557/APJCP.2019.20.6.1833 31244307 35. Sadik NA Ahmed A Ahmed S The significance of serum levels of adiponectin, leptin, and hyaluronic acid in hepatocellular carcinoma of cirrhotic and noncirrhotic patients Hum Exp Toxicol 2012 31 4 311 321 10.1177/0960327111431091 22249387 36. Voumvouraki A Koulentaki M Notas G Sfakianaki O Kouroumalis E Serum surrogate markers of liver fibrosis in primary biliary cirrhosis Eur J Intern Med 2011 22 1 77 83 10.1016/j.ejim.2010.10.002 21238899 37. Sumie S Kawaguchi T Kuromatsu R Takata A Nakano M Satani M Total and high molecular weight adiponectin and hepatocellular carcinoma with HCV infection PLoS One 2011 6 11 e26840 10.1371/journal.pone.0026840 22110596 38. Ataseven H Bahcecioglu IH Kuzu N Yalniz M Celebi S Erensoy A The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection Mediat Inflamm 2006 2006 4 78380 39. Kotani K Wakai K Shibata A Fujita Y Ogimoto I Naito M Serum adiponectin multimer complexes and liver cancer risk in a large cohort study in Japan Asian Pac J Cancer Prev 2009 10 Suppl 87 90 20553088 40. Wang YY Lin SY Leptin in relation to hepatocellular carcinoma in patients with liver cirrhosis Horm Res 2003 60 4 185 190 14530607 41. Amer T El-Baz R Mokhtar AR El-Shaer S Elshazli R Settin A Genetic polymorphisms of IL-23R (rs7517847) and LEP (rs7799039) among Egyptian patients with hepatocellular carcinoma Arch Physiol Biochem 2017 123 5 279 285 10.1080/13813455.2017.1320680 28452232 42. Cai X Gan Y Fan Y Hu J Jin Y Chen F The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk Clin Transl Oncol 2014 16 2 166 172 10.1007/s12094-013-1056-7 23740135 43. Zhang S Jiang J Chen Z Wang Y Tang W Liu C Investigation of LEP and LEPR polymorphisms with the risk of hepatocellular carcinoma: a case-control study in eastern Chinese Han population Onco Targets Ther 2018 11 2083 2089 10.2147/OTT.S153931 29695916 44. Siegel AB Goyal A Salomao M Wang S Lee V Hsu C Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients Oncology 2015 88 1 57 68 10.1159/000367971 25300295 45. Shen J Yeh CC Wang Q Gurvich I Siegel AB Santella RM Plasma adiponectin and hepatocellular carcinoma survival among patients without liver transplantation Anticancer Res 2016 36 10 5307 5314 10.21873/anticanres.11103 27798893 46. Shin E Yu YD Kim DS Won NH Adiponectin receptor expression predicts favorable prognosis in cases of hepatocellular carcinoma Pathol Oncol Res 2014 20 3 667 675 10.1007/s12253-014-9747-0 24619866 47. Watanabe N Takai K Imai K Shimizu M Naiki T Nagaki M Increased levels of serum leptin are a risk factor for the recurrence of stage I/II hepatocellular carcinoma after curative treatment J Clin Biochem Nutr 2011 49 3 153 158 10.3164/jcbn.10-149 22128212 48. Wang SN Yang SF Tsai HH Lee KT Yeh YT Increased adiponectin associated with poor survival in hepatocellular carcinoma J Gastroenterol 2014 49 9 1342 1351 10.1007/s00535-013-0898-7 24132578 49. Wang SN Yeh YT Yang SF Chai CY Lee KT Potential role of leptin expression in hepatocellular carcinoma J Clin Pathol 2006 59 9 930 934 10.1136/jcp.2005.035477 16565221 50. Wei T Ye P Peng X Wu LL Yu GY Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies Oncotarget 2016 7 30 48671 48691 10.18632/oncotarget.8932 27119501 51. Song RR Gu XL Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma Tumour Biol 2015 36 4 2983 2992 10.1007/s13277-014-2931-8 25492487 52. Skibola CF Holly EA Forrest MS Hubbard A Bracci PM Skibola DR Body mass index, leptin and leptin receptor polymorphisms, and non-hodgkin lymphoma Cancer Epidemiol Biomark Prev 2004 13 5 779 786 53. Hoffstedt J Eriksson P Mottagui-Tabar S Arner P A polymorphism in the leptin promoter region (−2548 G/A) influences gene expression and adipose tissue secretion of leptin Horm Metab Res 2002 34 7 355 359 10.1055/s-2002-33466 12189581 54. Liu P Shi H Huang C Shu H Liu R Yang Y Association of LEP A19G polymorphism with cancer risk: a systematic review and pooled analysis Tumour Biol 2014 35 8 8133 8141 10.1007/s13277-014-2088-5 24845032 55. Yang Y Liu P Guo F Liu R Yang Y Huang C Genetic G2548A polymorphism of leptin gene and risk of cancer: a meta-analysis of 6860 cases and 7956 controls J BUON 2014 19 4 1096 1104 25536622 56. Liu Y Wu H Zhu Y Gao Y Genetic association between leptin-2548G/A polymorphism and risk of cancer: a meta analysis Int J Clin Exp Med 2015 8 1 448 455 25785016 57. Yoon YS Kwon AR Lee YK Oh SW Circulating adipokines and risk of obesity related cancers: a systematic review and meta-analysis Obes Res Clin Pract 2019 13 4 329 339 10.1016/j.orcp.2019.03.006 31003933 58. Ye J, Liang Z, Liang Q, Zhang J, Mao S, Liang R. Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis. Lipids Health Dis. 2015;14(1). 59. Saxena NK Sharma D Ding X Lin S Marra F Merlin D Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells Cancer Res 2007 67 6 2497 2507 10.1158/0008-5472.CAN-06-3075 17363567 60. Zhou Q Lui VW Yeo W Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma Future Oncol 2011 7 10 1149 1167 10.2217/fon.11.95 21992728 61. Dupont J Reverchon M Cloix L Froment P Ramé C Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer Int J Dev Biol 2012 56 10–12 959 967 10.1387/ijdb.120134jd 23417417 62. Wauman J Tavernier J Leptin receptor signaling: pathways to leptin resistance Front Biosci (Landmark Ed) 2011 16 2771 2793 10.2741/3885 21622208 63. El-Habr EA Levidou G Trigka EA Sakalidou J Piperi C Chatziandreou I Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development Virchows Arch 2014 465 4 473 485 10.1007/s00428-014-1641-3 25146167 64. Pietrzyk L Torres A Maciejewski R Torres K Obesity and obese-related chronic low-grade inflammation in promotion of colorectal cancer development Asian Pac J Cancer Prev 2015 16 10 4161 4168 10.7314/APJCP.2015.16.10.4161 26028066 65. Polyzos SA Kountouras J Zavos C Deretzi G The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature J Clin Gastroenterol 2011 45 1 50 54 10.1097/MCG.0b013e3181ec5c66 20717042 66. Mittenbuhler MJ Sprenger HG Gruber S Wunderlich CM Kern L Bruning JC Hepatic leptin receptor expression can partially compensate for IL-6Ralpha deficiency in DEN-induced hepatocellular carcinoma Mol Metab 2018 17 122 133 10.1016/j.molmet.2018.08.010 30224299 67. Perrier S Jarde T Adiponectin, an anti-carcinogenic hormone? A systematic review on breast, colorectal, liver and prostate cancer Curr Med Chem 2012 19 32 5501 5512 10.2174/092986712803833137 22876928 68. Nazmy EA El-Khouly OA Zaki MMA Elsherbiny NM Said E Al-Gayyar MMH Targeting p53/TRAIL/caspase-8 signaling by adiponectin reverses thioacetamide-induced hepatocellular carcinoma in rats Environ Toxicol Pharmacol 2019 72 103240 10.1016/j.etap.2019.103240 31421311 69. Al-Gayyar MM Abbas A Hamdan AM Chemopreventive and hepatoprotective roles of adiponectin (SULF2 inhibitor) in hepatocelluar carcinoma Biol Chem 2016 397 3 257 267 10.1515/hsz-2015-0265 26733159 70. Manieri E Herrera-Melle L Mora A Tomás-Loba A Leiva-Vega L Fernández DI Adiponectin accounts for gender differences in hepatocellular carcinoma incidence J Exp Med 2019 216 5 1108 1119 10.1084/jem.20181288 30944152 71. Corbetta S Redaelli A Pozzi M Bovo G Ratti L Redaelli E Fibrosis is associated with adiponectin resistance in chronic hepatitis C virus infection Eur J Clin Investig 2011 41 8 898 905 10.1111/j.1365-2362.2011.02498.x 21539538 72. Barb D Neuwirth A Mantzoros CS Balk SP Adiponectin signals in prostate cancer cells through Akt to activate the mammalian target of rapamycin pathway Endocr Relat Cancer 2007 14 4 995 1005 10.1677/ERC-06-0091 18045951